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R
andomized  controlled  trials,  when  they 
are  appropriately  designed,  conducted  and 
 reported, represent the gold standard in evalu-
ating  health  care  interventions.  However,  randomized 
trials can yield biased results if they lack methodological 
rigour.1 To assess a trial accurately, readers of a published 
report  need  complete,  clear  and  transparent  informa-
tion on its methodology and findings. Unfortunately, at-
tempted assessments frequently fail because authors of 
many trial reports neglect to provide lucid and complete 
descriptions of that critical information.2–4
That lack of adequate reporting fuelled the develop-
ment of the original CONSORT (Consolidated Standards 
of Reporting Trials) statement in 1996  5 and its revision 5 
years later.6–8 While those statements improved the re-
porting quality for some randomized controlled trials,9,  10 
many  trial  reports  still  remain  inadequate.2  Further-
more, new methodological evidence and additional ex-
perience has accumulated since the last revision in 2001. 
Consequently, we organized a CONSORT Group meeting 
to update the 2001 statement.6–8 We introduce here the 
result of that process, CONSORT 2010.
Intent of CONSORT 2010
The CONSORT 2010 Statement is this paper including 
the 25-item checklist in the table (see Table 1) and the 
flow diagram (see Fig. 1). It provides guidance for re-
porting all randomized controlled trials, but focuses on 
the most common design type—individually random-
ized, 2-group parallel trials. Other trial designs, such 
as cluster randomized trials and non-inferiority trials, 
require  varying  amounts  of  additional  information. 
CONSORT extensions for these designs,11, 12 and other 
CONSORT products, can be found through the CON-
SORT  website  (www.consort-statement.org).  Along 
with  the  CONSORT  statement,  we  have  updated  the 
explanation  and  elaboration  article,13  which  explains 
the inclusion of each checklist item, provides methodo-
logical  background  and  gives  published  examples  of 
transparent reporting.
Diligent adherence by authors to the checklist items 
facilitates clarity, completeness and transparency of re-
porting. Explicit descriptions, not ambiguity or omis-
sion, best serve the interests of all readers. Note that the Open Medicine 2010;4(1):e61
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CONSORT 2010 Statement does not include recommen-
dations for designing, conducting and analyzing trials. 
It solely addresses the reporting of what was done and 
what was found.
Nevertheless, CONSORT does indirectly affect design 
and conduct. Transparent reporting reveals deficiencies 
in research if they exist. Thus, investigators who conduct 
inadequate  trials,  but  who  must  transparently  report, 
should not be able to pass through the publication pro-
cess without revelation of their trial’s inadequacies. That 
emerging  reality  should  provide  impetus  to  improved 
trial design and conduct in the future, a secondary in-
direct goal of our work. Moreover, CONSORT can help 
researchers in designing their trial.
Background to CONSORT
Efforts  to  improve  the  reporting  of  randomized  con-
trolled trials accelerated in the mid-1990s, spurred part-
ly by methodological research. Researchers had shown 
for many years that authors reported such trials poorly, 
and empirical evidence began to accumulate that some 
poorly  conducted  or  poorly  reported  aspects  of  trials 
were associated with bias.14 Two initiatives aimed at de-
veloping reporting guidelines culminated in one of us 
(DM) and Drummond Rennie organizing the first CON-
SORT  statement  in  1996.5  Further  methodological  re-
search on similar topics reinforced earlier findings15 and 
fed into the revision of 2001.6–8 Subsequently, the ex-
panding body of methodological research informed the 
refinement of CONSORT 2010. More than 700 studies 
comprise the CONSORT database (located on the CON-
SORT website), which provides the empirical evidence to 
underpin the CONSORT initiative.
Indeed, CONSORT Group members continually mon-
itor the literature. Information gleaned from these ef-
forts provides an evidence base on which to update the 
CONSORT  statement.  We  add,  drop  or  modify  items 
based on that evidence and the recommendations of the 
CONSORT Group, an international and eclectic group of 
clinical trialists, statisticians, epidemiologists and bio-
medical editors. The CONSORT Executive (KFS, DGA, 
DM) strives for a balance of established and emerging 
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Figure 1: Flow diagram of the progress through the phases of a parallel randomized trial of 2 groups  
(that is, enrolment, intervention allocation, follow-up, and data analysis).Open Medicine 2010;4(1):e62
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researchers. The membership of the group is dynamic. 
As our work expands in response to emerging projects 
and needed expertise, we invite new members to con-
tribute. As such, CONSORT continually assimilates new 
ideas and perspectives. That process informs the con-
tinually evolving CONSORT statement.
Over  time,  CONSORT  has  garnered  much  support. 
More  than  400  journals,  published  around  the  world 
and in many languages, have explicitly supported the 
CONSORT statement. Many other health care journals 
support it without our knowledge. Moreover, thousands 
more have implicitly supported it with the endorsement 
of the CONSORT statement by the International Com-
mittee  of  Medical  Journal  Editors  (www.icmje.org). 
Other prominent editorial groups, the Council of Science 
Editors and the World Association of Medical Editors, 
officially support CONSORT. That support seems war-
ranted: when used by authors and journals, CONSORT 
seems to improve reporting.9
Development of CONSORT 2010
Thirty-one members of the CONSORT 2010 Group met 
in Montebello, Canada, in January 2007 to update the 
2001 CONSORT statement. In addition to the accumulat-
ing evidence relating to existing checklist items, several 
new issues had come to prominence since 2001. Some 
participants were given primary responsibility for aggre-
gating and synthesizing the relevant evidence on a par-
ticular checklist item of interest. Based on that evidence, 
the group deliberated the value of each item. As in prior 
CONSORT  versions,  we  kept  only  those  items  deemed 
absolutely fundamental to reporting a randomized con-
trolled trial. Moreover, an item may be fundamental to a 
trial but not included, such as approval by an institutional 
ethical  review  board,  because  funding 
bodies  strictly  enforce  ethical  review 
and  medical  journals  usually  address 
reporting ethical review in their instruc-
tions for authors. Other items may seem 
desirable, such as reporting on whether 
on-site monitoring was done, but a lack 
of empirical evidence or any consensus 
on  their  value  cautions  against  inclu-
sion at this point. The CONSORT 2010 
Statement thus addresses the minimum 
criteria, although that should not deter 
authors  from  including  other  informa-
tion if they consider it important.
After  the  meeting,  the  CONSORT 
Executive  convened  teleconferences 
and meetings to revise the checklist. After 7 major iter-
ations, a revised checklist was distributed to the larger 
group for feedback. With that feedback, the executive 
met twice in person to consider all the comments and 
to produce a penultimate version. That served as the 
basis for writing the first draft of this paper, which was 
then distributed to the group for feedback. After con-
sideration  of  their  comments,  the  executive  finalized 
the statement.
The CONSORT Executive then drafted an updated ex-
planation and elaboration manuscript, with assistance 
from other members of the larger group. The substance 
of the 2007 CONSORT meeting provided the material 
for the update. The updated explanation and elaboration 
manuscript was distributed to the entire group for addi-
tions,  deletions  and  changes.  That  final  iterative  pro-
cess converged to the CONSORT 2010 Explanation and 
Elaboration.13
Changes in CONSORT 2010
The revision process resulted in evolutionary, not revo-
lutionary,  changes  to  the  checklist  (Table  1),  and  the 
flow diagram was not modified except for 1 word (Fig. 
1).  Moreover,  because  other  reporting  guidelines  aug-
menting the checklist refer to item numbers, we kept the 
existing items under their previous item numbers except 
for some renumbering of items 2 to 5. We added addi-
tional items either as a sub-item under an existing item, 
an entirely new item number at the end of the checklist, 
or (with item 3) an interjected item into a renumbered 
segment. We have summarized the noteworthy general 
changes in Box 1 and specific changes in Box 2. The CON-
SORT website contains a side-by-side comparison of the 
2001 and 2010 versions.
Box 1: Noteworthy general changes in CONSORT 2010 Statement
•  We simplifi  ed and clarifi  ed the wording, such as in items 1, 8, 10, 13, 15, 16, 18, 
19 and 21. 
•  We improved consistency of style across the items by removing the 
imperative verbs that were in the 2001 version.
•  We enhanced specifi  city of appraisal by breaking some items into sub-items. 
Many journals expect authors to complete a CONSORT checklist indicating 
where in the manuscript the items have been addressed. Experience with 
the checklist noted pragmatic diffi   culties when an item comprised multiple 
elements. For example, item 4 addresses eligibility of participants and the 
settings and locations of data collection. With the 2001 version, an author 
could provide a page number for that item on the checklist, but might have 
reported only eligibility in the paper, for example, and not reported the set-
tings and locations. CONSORT 2010 relieves obfuscations and forces authors 
to provide page numbers in the checklist for both eligibility and settings.Open Medicine 2010;4(1):e63
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Implications and limitations
We developed CONSORT 2010 to assist authors in writ-
ing reports of randomized controlled trials, editors and 
peer reviewers in reviewing manuscripts for publication, 
and readers in critically appraising published articles. 
The CONSORT 2010 Explanation and Elaboration pro-
vides elucidation and context to the checklist items. We 
strongly recommend using the explanation and elabora-
tion in conjunction with the checklist to foster complete, 
clear  and  transparent  reporting  and  aid  appraisal  of 
published trial reports.
CONSORT 2010 focuses predominantly on the 2-group, 
parallel  randomized  controlled  trial,  which  accounts 
for over half of trials in the literature.2 Most of the items 
from the CONSORT 2010 Statement, however, pertain to 
all types of randomized trials. Nevertheless, some types 
of trials or trial situations dictate the need for additional 
information in the trial report. When in doubt, authors, 
editors and readers should consult the CONSORT website 
for any CONSORT extensions, expansions (amplifications), 
implementations or other guidance that may be relevant.
The evidence-based approach we have used for CON-
SORT also served as a model for development of other 
reporting guidelines, such as for reporting systematic re-
views and meta-analyses of studies evaluating interven-
tions,16 diagnostic studies,17 and observational studies.18 
The explicit goal of all these initiatives is to improve re-
porting. The Enhancing the Quality and Transparency of 
Health Research (EQUATOR) Network will facilitate de-
velopment of reporting guidelines and help disseminate 
the  guidelines:  www.equator-network.org  provides  in-
formation on all reporting guidelines in health research.
With CONSORT 2010, we again intentionally declined 
to produce a rigid structure for the reporting of random-
ized trials. Indeed, SORT    19 tried a rigid format, and it 
failed in a pilot run with an editor and authors.20 Con-
sequently, the format of articles should abide by journal 
style, editorial directions, the traditions of the research 
field addressed, and, where possible, author preferences. 
We do not wish to standardize the structure of reporting. 
Authors  should  simply  address  checklist  items  some-
where in the article, with ample detail and lucidity. That 
stated, we think that manuscripts benefit from frequent 
subheadings  within  the  major  sections,  especially  the 
methods and results sections.
CONSORT urges completeness, clarity and transparen-
cy of reporting, which simply reflects the actual trial design 
and  conduct.  However,  as  a  potential  drawback,  a  re-
porting guideline might encourage some authors to report 
fictitiously the information suggested by the guidance rath-
er than what was actually done. Authors, peer reviewers 
and editors should vigilantly guard against that potential 
drawback and refer, for example, to trial protocols, to infor-
mation on trial registers and to regulatory agency websites. 
Moreover, the CONSORT 2010 Statement does not include 
recommendations for designing and conducting random-
ized trials. The items should elicit clear pronouncements 
of how and what the authors did, but do not contain any 
judgments on how and what the authors should have done. 
Thus, CONSORT 2010 is not intended as an instrument to 
evaluate the quality of a trial. Nor is it appropriate to use the 
checklist to construct a “quality score.”
Nevertheless, we suggest that researchers begin trials 
with their end publication in mind. Poor reporting allows 
authors, intentionally or inadvertently, to escape scru-
tiny of any weak aspects of their trials. However, with 
wide adoption of CONSORT by journals and editorial 
groups, most authors should have to report transparent-
ly all important aspects of their trial. The ensuing scru-
tiny rewards well-conducted trials and penalizes poorly 
conducted trials. Thus, investigators should understand 
the CONSORT 2010 reporting guidelines before starting 
a trial as a further incentive to design and conduct their 
trials according to rigorous standards.
CONSORT 2010 supplants the prior version published in 
2001. Any support for the earlier version accumulated from 
journals or editorial groups will automatically extend to 
this newer version, unless specifically requested otherwise. 
Journals that do not currently support CONSORT may do 
so by registering on the CONSORT website. If a journal sup-
ports or endorses CONSORT 2010, it should cite one of the 
original versions of CONSORT 2010, the CONSORT 2010 
Explanation and Elaboration, and the CONSORT website 
in their “Instructions to authors.” We suggest that auth-
ors who wish to cite CONSORT should cite this or another 
of the original journal versions of CONSORT 2010 State-
ment, and, if appropriate, the CONSORT 2010 Explanation 
and Elaboration.13 All CONSORT material can be accessed 
through the original publishing journals or the CONSORT 
website. Groups or individuals who desire to translate the 
CONSORT  2010  Statement  into  other  languages  should 
first consult the CONSORT policy statement on the website.
We  emphasize  that  CONSORT  2010  represents  an 
evolving  guideline.  It  requires  perpetual  reappraisal 
and, if necessary, modifications. In the future we will 
further revise the CONSORT material considering com-
ments,  criticisms,  experiences  and  accumulating  new 
evidence. We invite readers to submit recommendations 
via the CONSORT website.Open Medicine 2010;4(1):e64
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Box 2: Noteworthy speciﬁ  c changes in CONSORT 2010 Statement
Item 1b (title and abstract) We added a sub-item on providing a structured summary of trial design, methods, results, and 
conclusions and referenced the CONSORT for abstracts article21
Item 2b (introduction) We added a new sub-item (formerly item 5 in CONSORT 2001) on “Specifi  c objectives or hypotheses”
Item 3a (trial design) We added a new item including this sub-item to clarify the basic trial design (such as parallel group, 
crossover, cluster) and the allocation ratio
Item 3b (trial design) We added a new sub-item that addresses any important changes to methods after trial 
commencement, with a discussion of reasons
Item 4 (participants Formerly item 3 in CONSORT 2001
Item 5 (interventions) Formerly item 4 in CONSORT 2001. We encouraged greater specifi  city by stating that descriptions 
of interventions should include “suffi   cient details to allow replication”3
Item 6 (outcomes) We added a sub-item on identifying any changes to the primary and secondary outcome 
(endpoint) measures after the trial started. This followed from empirical evidence that authors 
frequently provide analyses of outcomes in their published papers that were not the pre-specifi  ed 
primary and secondary outcomes in their protocols, while ignoring their pre-specifi  ed outcomes 
(that is, selective outcome reporting).4,22  We eliminated text on any methods used to enhance the 
quality of measurements
Item 9 (allocation concealment 
   mechanism)
We reworded this to include mechanism in both the report topic and the descriptor to reinforce 
that authors should report the actual steps taken to ensure allocation concealment rather than 
simply report imprecise, perhaps banal, assurances of concealment
Item 11 (blinding) We added the specifi  cation of how blinding was done and, if relevant, a description of the similarity 
of interventions and procedures. We also eliminated text on “how the success of blinding (masking) 
was assessed” because of a lack of empirical evidence supporting the practice as well as theoretical 
concerns about the validity of any such assessment23,24
Item 12a (statistical methods) We added that statistical methods should also be provided for analysis of secondary outcomes
Sub-item 14b (recruitment) Based on empirical research, we added a sub-item on “Why the trial ended or was stopped”25
Item 15 (baseline data) We specifi  ed “A table” to clarify that baseline and clinical characteristics of each group are most 
clearly expressed in a table
Item 16 (numbers analyzed) We replaced mention of “intention to treat” analysis, a widely misused term, by a more explicit 
request for information about retaining participants in their original assigned groups26
Sub-item 17b (outcomes and 
   estimation)
For appropriate clinical interpretability, prevailing experience suggested the addition of “For binary 
outcomes, presentation of both relative and absolute eff  ect sizes is recommended”27
Item 19 (harms) We included a reference to the CONSORT paper on harms28
Item 20 (limitations) We changed the topic from “Interpretation” and supplanted the prior text with a sentence focusing 
on the reporting of sources of potential bias and imprecision
Item 22 (interpretation) We changed the topic from “Overall evidence.” Indeed, we understand that authors should be 
allowed leeway for interpretation under this nebulous heading. However, the CONSORT Group 
expressed concerns that conclusions in papers frequently misrepresented the actual analytical 
results and that harms were ignored or marginalized. Therefore, we changed the checklist item to 
include the concepts of results matching interpretations and of benefi  ts being balanced with harms
Item 23 (registration) We added a new item on trial registration. Empirical evidence supports the need for trial registration, 
and recent requirements by journal editors have fostered compliance29
Item 24 (protocol) We added a new item on availability of the trial protocol. Empirical evidence suggests that authors 
often ignore, in the conduct and reporting of their trial, what they stated in the protocol.4,22 Hence, 
availability of the protocol can instigate adherence to the protocol before publication and facilitate 
assessment of adherence after publication
Item 25 (funding) We added a new item on funding. Empirical evidence points toward funding source sometimes 
being associated with estimated treatment eff  ects30Open Medicine 2010;4(1):e65
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